{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:04:29Z","timestamp":1784113469976,"version":"3.55.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institute of Health","doi-asserted-by":"publisher","award":["R01 5R01CA231210"],"award-info":[{"award-number":["R01 5R01CA231210"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although preclinical studies consistently indicate that sulfasalazine (SAS) and disulfiram (DSF) are promising agents for the prevention and treatment of lung cancer, their clinical efficacy is limited. This discrepancy is attributed to the poor bioavailability of the drugs. Therefore, in the present study, we explored whether delivery of lower doses of SAS and DSF in nano self-emulsifying drug delivery systems (Nano-SEDDS) improves their potency and efficacy in suppressing malignant progression of lung tumors. Mice were treated with the tobacco smoke carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and once lung adenoma developed, high doses of free SAS (250\u2005mg\/kg) + DSF (100\u2005mg\/kg) or SEDDS formulations containing lower doses of SAS + DSF (40\u2005mg\/kg SAS + 8, 16 or 40\u2005mg\/kg DSF) were administered by oral gavage, every other day, for 10 weeks. Although the doses of SAS and DSF contained in SAS + DSF-SEDDS were about 6-fold and 3\u201315-fold lower, respectively, than the doses of the respective free drugs, SAS + DSF-SEDDS was more effective than free SAS + DSF in reducing the multiplicity of bigger lung tumors (\u22651\u2005mm). These effects were paralleled by significant reductions in the multiplicity of adenoma with progression and adenocarcinoma histopathological lesions. Also, lung tumors from mice treated with SAS + DSF-SEDDS exhibited an increase in the level of 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA), lipid peroxidation products. Overall, our results show that the Nano-SEDDS formulation of SAS + DSF is a promising approach to enhance the potency and efficacy of the drugs for lung cancer chemo-interception and treatment.<\/jats:p>","DOI":"10.1093\/carcin\/bgaf075","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T12:48:30Z","timestamp":1761482910000},"source":"Crossref","is-referenced-by-count":1,"title":["Lung cancer chemo-interception by sulfasalazine and disulfiram codelivered using a nano self-emulsifying drug delivery system in mice"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-939X","authenticated-orcid":false,"given":"Fekadu","family":"Kassie","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, University of Minnesota , Saint Paul, MN 55108 ,","place":["United States"]},{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-8946","authenticated-orcid":false,"given":"Kevin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California , Irvine, CA 92697 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6093-1552","authenticated-orcid":false,"given":"Katherine","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences , Pomona, CA 91766 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0208-2756","authenticated-orcid":false,"given":"Mohammed Riaz Hasan","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences , Pomona, CA 91766 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6918-2821","authenticated-orcid":false,"given":"Jeffrey","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences , Pomona, CA 91766 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2463-6233","authenticated-orcid":false,"given":"Sunil","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences , Pomona, CA 91766 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2493-1527","authenticated-orcid":false,"given":"Xueqing","family":"Liang","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Minnesota , Saint Paul, MN 55108 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-8177","authenticated-orcid":false,"given":"Davis","family":"Seelig","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Minnesota , Saint Paul, MN 55108 ,","place":["United States"]},{"name":"Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-308X","authenticated-orcid":false,"given":"Preshita","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences , Pomona, CA 91766 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2026071506190318000_bgaf075-B1","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1158\/0008-5472.CAN-06-3191","article-title":"Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL","volume":"67","author":"Lay","year":"2007","journal-title":"Cancer Res"},{"key":"2026071506190318000_bgaf075-B2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00280-008-0894-4","article-title":"The x\u2212c cystine\/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine","volume":"64","author":"Guan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071506190318000_bgaf075-B3","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41388-018-0307-z","article-title":"xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression","volume":"37","author":"Ji","year":"2018","journal-title":"Oncogene"},{"key":"2026071506190318000_bgaf075-B4","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI124049","article-title":"Suppression of the SLC7A11\/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma","volume":"130","author":"Hu","year":"2020","journal-title":"J Clin Invest"},{"key":"2026071506190318000_bgaf075-B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/carcin\/bgad020","article-title":"Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice","volume":"44","author":"Bagherpoor","year":"2023","journal-title":"Carcinogenesis"},{"key":"2026071506190318000_bgaf075-B6","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/0008-5472.CAN-09-3752","article-title":"Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"key":"2026071506190318000_bgaf075-B7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.bbrc.2014.03.047","article-title":"Inhibitory effect of Disulfiram\/copper complex on non-small cell lung cancer cells","volume":"446","author":"Duan","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"2026071506190318000_bgaf075-B8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2014-0424","article-title":"A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer","volume":"20","author":"Nechushtan","year":"2015","journal-title":"Oncologist"},{"key":"2026071506190318000_bgaf075-B9","doi-asserted-by":"publisher","first-page":"58516","DOI":"10.18632\/oncotarget.11305","article-title":"Targeting ALDH1A1 by disulfiram\/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"2026071506190318000_bgaf075-B10","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/cas.13309","article-title":"Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer","volume":"108","author":"Otsubo","year":"2017","journal-title":"Cancer Sci"},{"key":"2026071506190318000_bgaf075-B11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10120-016-0610-8","article-title":"Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"2026071506190318000_bgaf075-B12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/1471-2407-9-372","article-title":"Early termination of ISRCTN45828668, a phase \u00bd prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults","volume":"9","author":"Robe","year":"2009","journal-title":"BMC Cancer"},{"key":"2026071506190318000_bgaf075-B13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-021-08242-4","article-title":"A phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker","volume":"21","author":"Kelley","year":"2021","journal-title":"BMC Cancer"},{"key":"2026071506190318000_bgaf075-B14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s10637-022-01271-1","article-title":"Phase II study of disulfiram and cisplatin in refractory germ cell tumors. The GCT-SK-006 phase II trial","volume":"40","author":"Mego","year":"2022","journal-title":"Invest New Drugs"},{"key":"2026071506190318000_bgaf075-B15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/pcan.2013.28","article-title":"Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer","volume":"16","author":"Schweizer","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026071506190318000_bgaf075-B16","first-page":"107","article-title":"Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment [Spanish]","volume":"18","author":"Guastavino","year":"1988","journal-title":"Acta Gastroenterol Latinoam"},{"key":"2026071506190318000_bgaf075-B17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40199-019-00308-w","article-title":"Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy","volume":"27","author":"Farooq","year":"2019","journal-title":"DARU J Pharm Sci"},{"key":"2026071506190318000_bgaf075-B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/mp050113v","article-title":"Breast cancer resistance protein (Bcrp\/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse","volume":"3","author":"Zaher","year":"2006","journal-title":"Mol Pharm"},{"key":"2026071506190318000_bgaf075-B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/FPC.0000000000000509","article-title":"PharmGKB summary: disulfiram pathway","volume":"33","author":"Gonzalez-Suarez","year":"2023","journal-title":"Pharmacogenet Genomics"},{"key":"2026071506190318000_bgaf075-B20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","article-title":"Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc\u2212 cystine transporter: a new action for an old drug","volume":"15","author":"Gout","year":"2001","journal-title":"Leukemia"},{"key":"2026071506190318000_bgaf075-B21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/pharmaceutics16091194","article-title":"Powder self-emulsifying drug delivery system for mitotane: in vitro and in vivo evaluation","volume":"16","author":"Skiba","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026071506190318000_bgaf075-B22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41597-023-02812-w","article-title":"A dataset of formulation compositions for self-emulsifying drug delivery systems","volume":"10","author":"Zaslavsky","year":"2023","journal-title":"Sci Data"},{"key":"2026071506190318000_bgaf075-B23","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.2174\/03666220606143443","article-title":"Self-emulsifying drug delivery system for oral anticancer therapy: constraints and recent development","volume":"28","author":"Pandya","year":"2022","journal-title":"Curr Pharm Des"},{"key":"2026071506190318000_bgaf075-B24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s13346-019-00619-0","article-title":"Loratadine self-microemulsifying drug delivery systems (SMEDDS) in combination with sulforaphane for the synergistic chemoprevention of pancreatic cancer","volume":"9","author":"Desai","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"2026071506190318000_bgaf075-B25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11095-019-2737-x","article-title":"Efficacy and pharmacokinetic considerations of loratadine nanoformulations and its combinations for pancreatic cancer chemoprevention","volume":"37","author":"Desai","year":"2020","journal-title":"Pharm Res"},{"key":"2026071506190318000_bgaf075-B26","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"2026071506190318000_bgaf075-B27","author":"Desai"},{"key":"2026071506190318000_bgaf075-B28","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3892\/or.2013.2759","article-title":"Gender-dependent effects of gonadectomy on lung carcinogenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female and male A\/J mice","volume":"30","author":"Ninomiya","year":"2013","journal-title":"Oncol Rep"},{"key":"2026071506190318000_bgaf075-B29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/carcin\/bgr010","article-title":"Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A\/J mice","volume":"32","author":"Dagne","year":"2011","journal-title":"Carcinogenesis"},{"key":"2026071506190318000_bgaf075-B30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1158\/0008-5472.CAN-03-3376","article-title":"Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium","volume":"64","author":"Nikitin","year":"2004","journal-title":"Cancer Res"},{"key":"2026071506190318000_bgaf075-B31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/carcin\/bgac019","article-title":"Combinatory lung tumor inhibition by myo-inositol and iloprost\/rapamycin: a sociation with immunomodulation","volume":"43","author":"Kassie","year":"2022","journal-title":"Carcinogeneis"},{"key":"2026071506190318000_bgaf075-B32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/10428194.2024.2422843","article-title":"FDA-approved disulfiram induces ferroptosis via alteration of redox balance and lipid peroxidation and overcomes carfilzomib resistance in multiple myeloma","volume":"66","author":"Arkan","year":"2025","journal-title":"Leuk Lymphome"},{"key":"2026071506190318000_bgaf075-B33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2016.07.035","article-title":"Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer","volume":"381","author":"Roh","year":"2016","journal-title":"Cancer Lett"},{"key":"2026071506190318000_bgaf075-B34","first-page":"3164","article-title":"Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A\/J mouse","volume":"52","author":"Belinsky","year":"1992","journal-title":"Cancer Res"},{"key":"2026071506190318000_bgaf075-B35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/carcin\/bgg196","article-title":"Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A\/J mice","volume":"25","author":"Estensen","year":"2003","journal-title":"Carcinogenesis"},{"key":"2026071506190318000_bgaf075-B36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.31083\/j.fbl2808186","article-title":"Disulfiram\/copper induce ferroptosis in triple-negative breast cancer cell line MDA-MB-231","volume":"28","author":"Chu","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2026071506190318000_bgaf075-B37","doi-asserted-by":"publisher","first-page":"167455","DOI":"10.1016\/j.bbadis.2024.167455","article-title":"Disulfiram\/copper complex improves the effectiveness of the WEE1 inhibitor adavosertib in p53 deficient non-small cell lung cancer via ferroptosis","volume":"1870","author":"Liu","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026071506190318000_bgaf075-B38","doi-asserted-by":"publisher","first-page":"103007","DOI":"10.1016\/j.redox.2023.103007","article-title":"Inhibiting the compensatory elevation of xCT collaborates with disulfiram\/copper-induced GSH consumption for cascade ferroptosis and cuproptosis","volume":"69","author":"Zhang","year":"2024","journal-title":"Redox Biol"},{"key":"2026071506190318000_bgaf075-B39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/2211738508666200811104240","article-title":"Self-emulsifying drug delivery system improve oral bioavailability: role of excipients and physico-chemical characterization","volume":"8","author":"Zhu","year":"2020","journal-title":"Pharm Nanotechnol"},{"key":"2026071506190318000_bgaf075-B40","doi-asserted-by":"publisher","first-page":"26895","DOI":"10.1038\/srep26895","article-title":"Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity","volume":"6","author":"Valicherla","year":"2016","journal-title":"Sci Rep"},{"key":"2026071506190318000_bgaf075-B41","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1111\/j.1749-6632.2010.05708.x","article-title":"Microanatomy of the intestinal lymphatic system","volume":"1207 Suppl 1","author":"Miller","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"2026071506190318000_bgaf075-B42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2125.1982.tb01415.x","article-title":"The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man","volume":"13","author":"Azadkhan","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"2026071506190318000_bgaf075-B43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jcmgh.2019.04.015","article-title":"Cystine\/glutamate antiporter (xCT) is required for chief cell plasticity after gastric injury","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026071506190318000_bgaf075-B44","doi-asserted-by":"publisher","first-page":"102416","DOI":"10.1016\/j.jddst.2021.102416","article-title":"Effect of carrier type and Tween\u00ae 80 concentration on the release of silymarin from amorphous solid dispersions","volume":"63","author":"Mohylyuk","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"key":"2026071506190318000_bgaf075-B45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/JTO.0000000000000456","article-title":"Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry","volume":"10","author":"Zhang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2026071506190318000_bgaf075-B46","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-07-1757","article-title":"Quantitative monitoring of adenocarcinoma development in rodents by magnetic resonance imaging","volume":"14","author":"Garbow","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026071506190318000_bgaf075-B47","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/0008-5472.CAN-03-3258","article-title":"Detection of primary lung tumors in rodents by magnetic resonance imaging","volume":"64","author":"Garbow","year":"2004","journal-title":"Cancer Res"},{"key":"2026071506190318000_bgaf075-B48","doi-asserted-by":"publisher","first-page":"741316","DOI":"10.3389\/fmolb.2021.741316","article-title":"Recent advances in repurposing disulfiram and disulfiram derivatives as copper-dependent anticancer agents","volume":"8","author":"Kannappan","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026071506190318000_bgaf075-B49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jhep.2023.03.016","article-title":"ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis","volume":"79","author":"He","year":"2023","journal-title":"J Hepatol"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgaf075\/65001878\/bgaf075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/46\/4\/bgaf075\/65001878\/bgaf075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/46\/4\/bgaf075\/65001878\/bgaf075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:19:16Z","timestamp":1784110756000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/doi\/10.1093\/carcin\/bgaf075\/8304840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgaf075","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]},"article-number":"bgaf075"}}